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Objectives: This study evaluated the incidence and outcomes of
secondary procedures for Type I endoleaks following endovascular aneu-
rysm repair (EVAR).
Methods: From 2002 to 2013, 2496 patients underwent EVAR for
treatment of nonruptured (n ¼ 2315; 93%) and ruptured (n ¼ 181; 7%)
abdominal aortic aneurysms (AAAs). Postoperative follow-up included clin-
ical examination, ultrasound, and computed tomography at 1, 6, and 12
months, and yearly thereafter. Patients with Type I endoleaks were either
observed without any intervention, underwent endovascular interventions,
or surgical explant. Data was prospectively collected.
Results: Of 2496 patients that underwent EVAR, over a mean follow-
up of 57 months, 202 (8%) patients were discovered to have Type I endo-
leaks from proximal (n ¼ 111; 55%), distal (n ¼ 69; 34%), or proximal and
distal (n ¼ 22; 11%) stent graft ﬁxation sites. The mean age was 74 years,
and the maximum AAA diameter was 6.0 cm. Indications for treatment
included asymptomatic Type I endoleaks (n ¼ 171; 85%), symptomatic
aneurysms (n ¼ 14; 7%), or aneurysm rupture (n ¼ 17; 8%). In 49 (24%)
patients, Type I endoleaks resolved without any further intervention. Treat-
ments included embolization procedures only in 17 (8%), stent graft exten-
sions only in 103 (51%), embolization and stent graft extensions in 19 (9%),
and stent graft explant in 14 (7%). Multiple endovascular procedures were
required in 41 (20%) patients. Overall operative mortality for all Type I
endoleaks was 1.5%; all deaths occurred in patients that presented with
ruptured AAAs (3/17; 18%).
Conclusions: Our single center long-term EVAR experience indicates
that 8% of patients developType I endoleaks. The vastmajority of Type I endo-
leaks can be treated by endovascular means with limited mortality, and embo-
lization procedures alone can be effective in select patients. If untreated, 24%
of Type I endoleaks resolve spontaneously, while 26% lead to AAA rupture.Prospective Multicenter International Trial of EndoAnchor Fixation
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Objectives: Endograft ﬁxation and sealing are important determi-
nants of durability after endovascular abdominal aortic aneurysm repair
(EVAR). This study was undertaken to assess the safety and efﬁcacy of
EndoAnchors to augment proximal ﬁxation and sealing in a globally-
setting.
Methods: The 149 subjects have been enrolled at 23 U.S. and four
European centers over 15 months through mid-April, 2013. EndoAnchors
implanted prophylactically at initial EVAR (“PRIMARIES,” N ¼ 111; 74%)
or therapeutically for existing type Ia endoleak/migration after the index
EVAR procedure (“REVISIONS,” N ¼ 38; 26%). The primary endpoint
was successful EndoAnchor deployment without type Ia endoleak/migra-
tion over time. A conical neck was deﬁned by diameter increase >10%
over 10 mm length.
Results: The endografts used were Endurant (57; 51%), Excluder
(30; 27%), and Zenith (24; 22%) in PRIMARIES, and Excluder (7; 18%),
AneuRx (10; 26%), Talent (6; 16%), Zenith (5; 13%), Endurant (5; 13%),
and other (5; 13%) in REVISIONS. Proximal necks averaged 18.6 6
11.2 mm in length (28% #10 mm), 25.1 6 4.5 mm in diameter, with 33
6 22 degrees of angulation; 41% were conical. An average of 5.3 EndoAn-
chors were implanted in PRIMARIES and 6.2 in REVISIONS. The most
common indication for EndoAnchor use was a hostile neck in PRIMARIES
(88%) and existing type Ia endoleak in REVISIONS (76%). Procedural
success was conﬁrmed in 99% (109/110) of the PRIMARIES and 92%
(35/38) in REVISIONS. Type Ia endoleaks were absent at 1-month in
96/99 (97%) of PRIMARIES and 32/36 (89%) of REVISIONS.
Conclusions: EndoAnchor use was associated with satisfactory early
results when high-risk anatomy was encountered at an initial EVAR proce-
dure and was successful in repairing most proximal neck problems in EVAR
revisions. Long-term data will be collected to assess the effectiveness of
EndoAnchors in preventing late complications.
